ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
UK regulator defends rapid approval of vaccine after Fauci criticism
ICON’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, comments on MHRA, the UK regulator, following their emergency use authorisation of the Pfizer COVID-19 vaccine.
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon on why the future of drug development involves decentralising parts of the clinical trial process.
New whitepaper details challenges and explores solutions to end AIDS epidemic
This article reports on ICON's new whitepaper "The evolution of HIV treatments: From PrEP to vaccines, where we are today and what’s next".
Moving from "on-site" to agile: The changing dynamic in study management
Pharmafocus features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
ICON talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter features a Q&A with EB McLindon on the inclusivity of decentralised clinical trials.
Clinical trials shift to hybrid approaches in the age of COVID-19 and beyond
An article examining the state of clinical trials for orthopedics, featuring expert commentary from ICON's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
ICON: patient-centric trial network showing results
Alison Liddy, Senior VP of Site & Patient Solutions, discusses ICON's new Accellacare clinical research network, and the importance of patient centricity.
Engaging the crowds
A thought leadership piece by Peter Schueler which considers the importance of patient engagement and enrollment in Alzheimer's clinical trials.
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
Pharma and biotech companies are shifting from traditional trial models to agile, patient-centric processes driven by digital technologies to improve R&D productivity.